Heart failure and diabetes

Česká verze

Authors: Ján Murín; Jozef Bulas
Authors place of work: I. interná klinika LF UK a Nemocnica Staré Mesto, UNB, Bratislava, prednostka doc. MUDr. Soňa Kiňová, PhD.
Published in the journal: Forum Diab 2013; 2(1): 18-22
Category: Komplikácie diabetu

Summary

Diabetes mellitus and heart failure are nowadays both diseases of epidemic characteristics. Diabetes seems to be an engine of heart failure development. More severe heart failure forms have more frequently presence of diabetes. This is true for both systolic and diastolic heart failure types. In the pathophysiology of heart failure in diabetics there is an influence of myocardial ischaemia, of metabolic (lipidic and diabetic) serum changes and of diabetic cardiomyopathy. Also activation of renin-angiotensin-aldosterone system is important, mainly the alternative pathway where enhanced activity of ACE2 enzyme seems to be present. Author presents clinical signs of heart failure here and also management of heart failure in diabetics. He is discussing the problem of strict versus of normal control of serum glycaemia and also pharmacologic treatment of diabetes, mostly from safety points of view. The topic is important for clinical practice and points to the management of heart failure in diabetics. The prevention is here better than the treatment.

Key words:
diabetes mellitus – heart failure – diabetic cardiomyopathy – antidiabetics

Zdroje

1. Mokáň M, Galajda P, Prídavková D et al. Prevalencia diabetes mellitus a metabolického syndrómu na Slovensku. Diabetes a obezita 2006; 6(12): 10–16.

2. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974; 34(1): 29–34.

3. Gottdiener JS, Arnold AM, Aurigemma GP et al. Predictors of congestive heart failure in the elderly: the Cardiovascular health study. J Am Coll Cardiol 2000; 35(6): 1628–1637.

4. Nichols GA, Hillier TA, Erbey JR et al. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001; 24(9): 1614–1619.

5. Arnold JM, Yusuf S, Young J et al. Prevention of heart failure in patients in the heart outcomes prevention evaluation (HOPE) study. Circulation 2003; 107(9): 1284–1290.

6. MERIT – HF Investigators. Effect of metoprolol CR/XL in chronic heart failure. Lancet 1999; 353(9169): 2001–2007.

7. Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European trial (COMET). Lancet 2003; 362(9377): 7–13.

8. Cohn JN, Tognoni A. A randomized trial of the angiotensin – receptor blocker valsartan in chronic heart failure. N Engl. J Med 2001; 345(23):1667–1675.

9. Iribarren C, Karter AJ, Go AS et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001; 103(22): 2668–2673.

10. Held C, Gerstein HC, Yusuf S et al. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 2007; 115(11): 1371–1375.

11. Jaffe AS, Spadaro JJ, Schechtman K et al. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J 1984; 108(1): 31–37.

12. Aguilar D, Solomon SD, Kober L et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction:the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 2004; 110(12): 1572–1578.

13. Das SR, Drazner MH, Yancy CW et al. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the studies of left ventricular dysfunction (SOLVD) prevention trial. Am Heart J; 2004; 148(5): 883–888.

14. Domanski M, Krause-Steinrauf H, Deedwania P et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 2003; 42(5): 914–922.

15. From AM, Leibson CL, Bursi F et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med 2006; 119(7): 591–599.

16. Hellerman JP, Jacobsen SJ, Gersh BJ et al. Heart failure after myocardial infarction: a review. Am J Med 2002; 113(4): 324–330.

17. Gustaffson I, Brendorp B, Seibaek M et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 2004; 43(5): 771–777.

18. Pijna IL, Buchter C. Heart failure in women. Cardiol Rev 2003; 11(6): 337–344.

19. Murarka S, Movahed MR. Diabetic cardiomyopathy. J Card Fail 2010; 16(12): 971–979.

20. Saunders J, Mathewkutty S, Drazner MH, MGuire DK. Cardiomyopathy in type 2 diabetes: update on pathophysiological mechanisms. Herz 2008; 33(3): 184–190.

21. Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 2009; 53(Suppl 5): S35-S42.

22. Rask-Madsen C, King GL. Mechanisms of disease: Endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 2007; 3(1): 46–56.

23. Khera A, Mc Guire DK. Management of diabetic dyslipidemia: need for reappraisal of the goals. Am J Cardiovasc Drugs 2005; 5(2): 83–91.

24. Mathewkutty S, McGuire DK. Platelet perturbations in diabetes: Implications for cardiovascular disease risk and treatment. Expert Rev Cardiovasc Ther 2009; 7(5): 541–549.

25. Lindsey JB, Cipollone F, Abdullah SM, McGuire DK. Receptor for advanced glycation end-poducts (RAGE). Cardiovascular implications. Diab Vasc Dis Res 2009; 6(1): 7–14.

26. Poormina IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circulation 2006; 98(5): 596–605.

27. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115(25): 3213–3223.

28. Pernický M, Karabová M, Murín J. Diabetes významne ovplyvňuje akútne srdcové zlyhanie a akútny koronárny syndróm. Cardiology letters 2012; 21(1): 86.

29. Villarreal FJ, Kim NN, Ungab GD et al. Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation 1993; 88(6): 2849–2861.

30. Dostal DE, Baker KN. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 1999; 85(7): 643–650.

31. Greenberg B, Quinones MA, Koilpillai C et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995; 91(10): 2573–2581.

32. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362(9386): 772–776.

33. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by doppler echocardiography. J Am Coll Cardiol 2006; 48(8): 1548–1551.

34. Poirier P, Bogaty P, Philippon F et al. Preclinical diabetic cardiomyopathy: relation of left ventricular diastolic dysfunction to cardiac autonomic neuropathy in men with uncomplicated well-controlled type 2 diabetes. Metabolism 2003; 52(8): 1056–1061.

35. Diamant M, Lamb HJ, Groeneveld Y et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 2003; 42(2): 328–335.

36. Berg TJ, Snorgaard O, Faber J et al. Serum levels of advanced glycation end-products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 1999; 22(7): 1186–1190.

37. Bertoni AG, Goff DC jr, D´Agostino RB jr. Diabetic cardiomyopathy and subclinical cardiovascular disease: the: multi-ethnic study of atherosclerosis (MESA). Diabetes Care 2006; 29(3): 588–594.

38. McMurray JJV, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and Treatment of acute and chronic heart failure 2012. Eur J Heart Fail 2012; 14(8): 803–869.

39. Swedberg K, Komajda M, Boehm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376(9744): 875–885.

40. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341(10): 709–717.

41. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348(14): 1309–1321.

42. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS). Lancet 1998; 352(9131): 854–865.

43. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358(24): 2560–2572.

44. The Action to Control CardiOvascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358(24): 2545–2553.

45. Nichols GA, Koro CE, Gullion CM et al. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 2005; 21(1): 51–57.

46. Smoke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 2005; 149(1): 168–174.

47. Massoudi FA, Inzucchi SE, Wang Y et al. Thiazolidinediones, metformin and outcomes in older patients with diabetes and heart failure. Circulation 2005; 111(5): 583–590.

48. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24): 2457–2471.

49. Komajda M, McMurray JJV, Beck-Nielsen et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010; 31(7): 824–831.